This study investigates locally advanced pancreatic cancer. It focuses on evaluating the effects of combining immunotherapy with chemotherapy.
The study evaluates the safety and effectiveness of this combination treatment. It looks into various outcomes such as changes in specific health markers and overall survival.
- Who can participate: Adults aged 18 to 75 with confirmed pancreatic ductal adenocarcinoma can join. Participants must not have received prior treatment for this cancer and must meet health criteria set by the study.
- Study details: Participants will receive a combination of investigational medication and chemotherapy. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.